2025 Europe Acute Migraine Drugs Market Revenue Opportunities Report
Description
The 2025 Europe Acute Migraine Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Acute Migraine Drugs Market in Europe are Eli Lilly, Amgen, Teva Pharmaceutical, and Pfizer. Eli Lilly has expanded its European presence through a distribution agreement with Organon for migraine drugs such as Emgality (galcanezumab) and RAYVOW (lasmiditan), enhancing drug availability across Europe. Amgen is recognized as a key global player focusing on strengthening its product portfolio in migraine treatment. Teva Pharmaceutical is notable for its migraine prevention drug AJOVY (fremanezumab), which is undergoing approval expansions for pediatric use and has reported positive Phase 3 trial results in China. Pfizer, in partnership with Biohaven, secured European Medicines Agency approval for Rimegepant, a CGRP receptor antagonist used in acute migraine relief.
These companies lead market innovations through novel drug formulations, regulatory approvals, and strategic collaborations aimed at the European market. The migraine drugs market in Europe generated approximately USD 1.77 billion in revenue in 2024 and is expected to grow at a CAGR of around 10.3% through 2030, driven partly by these companies’ activities. Their efforts include launching fast-acting CGRP antagonists for rapid relief, expanding pediatric indications, and leveraging OTC and prescription drug segments within well-developed healthcare infrastructures in countries like the UK, Germany, and France. This sustained focus supports a robust market growth trajectory for acute migraine therapies in Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Acute Migraine Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Acute Migraine Drugs Market in Europe are Eli Lilly, Amgen, Teva Pharmaceutical, and Pfizer. Eli Lilly has expanded its European presence through a distribution agreement with Organon for migraine drugs such as Emgality (galcanezumab) and RAYVOW (lasmiditan), enhancing drug availability across Europe. Amgen is recognized as a key global player focusing on strengthening its product portfolio in migraine treatment. Teva Pharmaceutical is notable for its migraine prevention drug AJOVY (fremanezumab), which is undergoing approval expansions for pediatric use and has reported positive Phase 3 trial results in China. Pfizer, in partnership with Biohaven, secured European Medicines Agency approval for Rimegepant, a CGRP receptor antagonist used in acute migraine relief.
These companies lead market innovations through novel drug formulations, regulatory approvals, and strategic collaborations aimed at the European market. The migraine drugs market in Europe generated approximately USD 1.77 billion in revenue in 2024 and is expected to grow at a CAGR of around 10.3% through 2030, driven partly by these companies’ activities. Their efforts include launching fast-acting CGRP antagonists for rapid relief, expanding pediatric indications, and leveraging OTC and prescription drug segments within well-developed healthcare infrastructures in countries like the UK, Germany, and France. This sustained focus supports a robust market growth trajectory for acute migraine therapies in Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
